The SURMOUNT-1 trial recorded 22.5% average weight loss at this dose, roughly 52 pounds
Stop this drug without delay and contact health care provider if pancreatitis is suspected (severe abdominal pain that may radiate to the back, with or without vomiting)
A stratified Cox proportional hazards model was used, with treatment as a fixed effect and trial-level cardiovascular risk as the stratification factor, to estimate hazard ratios (HRs) and confidence intervals (CIs) when comparing tirzepatide to the control
Most important she knows her stuff
However, the studies on the metabolic benefits of microdosing tirzepatide are still limited
Tirzepatide is injected subcutaneously into the abdomen, the upper outer thigh, or the back of the upper arm